Hematology and Oncology Study Experience

• Acute myelogenous leukemia (AML)
• Anal
• Anemia
• Anti-thrombin deficiency
• Bladder
• Brain
• Breast
• Cervical
• Chronic lymphocytic leukemia (CLL)
• Chronic myelogenous leukemia (CML)
• Colorectal
• Cutaneous T-cell lymphoma
• Gastric
• Glioblastoma multiforme (GBM)
• Hemophilia
• Hepatic
• Leptomeningeal carcinoma
• Melanoma
• Mucositis
• Multiple myeloma deficiency
• Myelodysplastic syndromes
• Myeloproliferative disease
• Non-Hodgkins lymphoma
• Non-small cell lung cancer (NSCLC)
• Ovary
• Pancreas
• Post-herpetic neuralgia (PHN)
• Prostate
• Renal cell
• Squamous cell carcinoma (SCCHN)
• Skin
• Thrombocythemia
• Thyroid
• Uterus

Therapeutic Experience

• Antiangiogenic agents
• Antisense therapy
• Biological response modifier (e.g., cytokines, MAb)
• Chemosensitizers
• Cytotoxics (systemic and topical)
• Gene therapy
• Hematopoeitic growth factors
• Hormonal therapy
• Radioisotopes
• Radiotherapy
• Regional administration
• Targeted therapy

Hematology/Oncology Study Experience

Awarded Phase Experience (last five years)

Study Site Experience

Biomarker Experience

PPD biomarker technology and research capabilities can be utilized to add value along the entire drug discovery and development process, including:

• Target discovery and clinical validation of candidate targets
• Increased understanding of drug effects
• Improved in vivo models of disease
• More rapid determination of efficacy, safety and optimal dosing regimens
• Patient stratification by disease sub-type and response to therapy

Our research yields biomarkers and information that enable more efficient discovery and development of new hematology and oncology therapeutics, as well as development of diagnostic tests for early disease detection. These biomarkers can also accurately determine disease sub-types and predict and monitor responses to therapy.